Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics has presented interim results from an investigator-sponsored Phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).
Subscribe to our email newsletter
Case studies were also presented on two patients with relapsed peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) who were treated with ADCETRIS. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.
Patients treated in the trial receive 1.8mg/kg of ADCETRIS every three weeks for up to a maximum of eight doses.
Patients who achieve partial remission or stable disease are eligible to receive an additional eight doses.
Study has found that eleven of 17 evaluable patients (65%) achieved an objective response, including seven complete remissions (CRs) and four partial remissions (PRs).
Six patients had stable disease. These investigator-assessed responses were observed in all three subtypes of CTCL.
In the PTCL case studies, PTCL-NOS is associated with a poor prognosis and there is no well-established standard of care, the study authors reported.
The first patient has achieved a PR with progression-free survival of eight months and overall survival of 22 months.
The second patient has achieved a CR which is still ongoing with a duration of more than 19 months.